Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.
Age at depressive onset (AAO) corresponds to unique symptomatology and clinical outcomes. Integration of genome-wide association study (GWAS) results with additional “omic” measures to evaluate AAO has not been reported and may reveal novel markers of susceptibility and/or resistance to major depressive disorder (MDD). To address this gap, we integrated genomics with metabolomics using data-driven network analysis to characterize and differentiate MDD based on AAO. This study first performed two GWAS for AAO as a continuous trait in (a) 486 adults from the Pharmacogenomic Research Network-Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS), and (b) 295 adults from the Combining Medications to Enhance Depression Outcomes (CO-MED) study. Variants from top signals were integrated with 153 p180-assayed metabolites to establish multi-omics network characterizations of early (
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
ISSN
Publication Date
Volume
Issue
Location
Related Subject Headings
- 3214 Pharmacology and pharmaceutical sciences
- 3206 Medical biotechnology
- 3205 Medical biochemistry and metabolomics
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Location
Related Subject Headings
- 3214 Pharmacology and pharmaceutical sciences
- 3206 Medical biotechnology
- 3205 Medical biochemistry and metabolomics